Updated

Teva Pharmaceutical's $125 million bid for BioXcel Therapeutics is drawing analyst attention for its potential upside, though observers cautioned that FDA approval risk and a competitive auction process could complicate the deal's outcome. The bid reflects Teva's continued efforts to expand its pipeline through targeted acquisitions, even as uncertainty remains over regulatory clearance and rival bidders for BioXcel's assets.